N@N

INTELLIPHARMACEUTICS INTERNA (NASDAQ:IPCI), Up By 6.13% ($0.21) After BUYINS.NET SqueezeTrigger Report Released on Monday, Febr

^{Published on 2012-02-07 05:40:39 - WOPRAI}
 

February 7, 2012 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, released a report on Monday, February 6th 2012 at 09:15:00 PST stating that INTELLIPHARMACEUTICS INTERNA (NASDAQ:IPCI) was expected to be Up After it crossed above its SqueezeTrigger Price of 3.39 on Monday, February 6th 2012. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=ipci&id=239901

From August 2009 to January 2012, an aggregate amount of 6710908 shares of IPCI have been shorted for a total dollar value of $20132724. The IPCI SqueezeTrigger price of $3.39 is the volume weighted average price that all shorts are short in shares of IPCI. There is still approximately $520,191 of potential short covering in shares of IPCI.

SqueezeTrigger.com has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger Price for each stock that has been shorted. The data has then been integrated into an automated trading platform which can be used to connect to a live online broker and automate your trading of short squeeze events. It is extremely powerful with lightening fast execution at a very low price. Both the trading software and SqueezeTrigger data feed are available at http://www.squeezetrigger.com .

INTELLIPHARMACEUTICS INTERNA (NASDAQ:IPCI) - Intellipharmaceutics International Inc. engages in the research, development, and manufacture of novel and generic controlled and targeted release oral solid dosage drugs. The companys patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the development of various existing and new pharmaceuticals. It has a pipeline of 15 products in various stages of development in therapeutic areas, including neurology, cardiovascular, and GIT. The companys lead generic product under development includes generic Focalin XR (dexmethylphenidate hydrochloride), an extended-release capsule for the treatment of attention deficit hyperactivity disorder. Intellipharmaceutics has a license and commercialization agreement with Par Pharmaceutical, Inc. for the development and commercialization of generic Focalin XR. In addition, the company has two generic products filed with the FDA, including a generic of Effexor XR (venlafaxine hydrochloride) and Protonix (delayed release pantoprazole sodium). Its lead non-generic product under development is Rexista oxycodone, an abuse- and alcohol-resistant controlled-release oral oxycodone formulation for the relief of pain. The company also has products under late stage development, which consist of venlafaxine hydrochloride, an extended-release capsule for the treatment of symptoms of depressive disorder, generalized anxiety disorder, social anxiety disorder, and panic disorder; and carvedilol phosphate, an extended-release capsule for the treatment of hypertension and heart conditions. The company was formerly known as IntelliPharmaCeutics Ltd. and changed its name to Intellipharmaceutics International Inc. in October 2009. IntelliPharmaCeutics International Inc. was founded in 1998 and is based in Toronto, Canada.

The SqueezeTrigger database of approximately 1 billion short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like SqueezeTrigger.com to access the data. Total Short Interest is the number of shares shorted but not yet covered, and is different from total short volume. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com

About BUYINS.NET

BUYINS.NET, http://www.buyins.net, monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market-maker surveillance system tracking market makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and all Threshold Security Lists daily for which stocks have naked short positions.

INVESTMENTS & TRADING

SqueezeTrigger -- 28 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts next move in stocks.

GATS -- tracks and quantifies known trading strategies.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. [symbol] has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net